Literature DB >> 28650937

Weak HIV Antibody Responses in Perinatally Infected Young Adults: Weak HIV Antibody Responses in Perinatally Infected Adults.

Allison R Kirkpatrick1, Aylin B Unsal, Joel N Blankson, Richard D Moore, Thomas C Quinn, Colleen Hadigan, Oliver Laeyendecker.   

Abstract

We compared the antibody response to HIV using 2 serologic cross-sectional incidence assays in adults with perinatally acquired HIV, to elite controllers and individuals exposed to antiretroviral therapy who were all infected as adults. Low antibody responses were seen more frequently in adults with perinatally acquired HIV, both overall and when stratified by viral suppression status.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28650937      PMCID： PMC5638694          DOI： 10.1097/INF.0000000000001649

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN： 0891-3668            Impact factor:   2.129


  12 in total

Review 1.  Beyond detuning: 10 years of progress and new challenges in the development and application of assays for HIV incidence estimation.

Authors:  Michael P Busch; Christopher D Pilcher; Timothy D Mastro; John Kaldor; Gaby Vercauteren; William Rodriguez; Christine Rousseau; Thomas M Rehle; Alex Welte; Megan D Averill; Jesus M Garcia Calleja
Journal:  AIDS       Date:  2010-11-27       Impact factor: 4.177

2.  Increased coronary vessel wall thickness in HIV-infected young adults.

Authors:  Khaled Z Abd-Elmoniem; Aylin B Unsal; Sarah Eshera; Jatin R Matta; Nancy Muldoon; Dorothea McAreavey; Julia B Purdy; Rohan Hazra; Colleen Hadigan; Ahmed M Gharib
Journal:  Clin Infect Dis       Date:  2014-08-25       Impact factor: 9.079

3.  Impact of HIV subtype on performance of the limiting antigen-avidity enzyme immunoassay, the bio-rad avidity assay, and the BED capture immunoassay in Rakai, Uganda.

Authors:  Andrew F Longosz; David Serwadda; Fred Nalugoda; Godfrey Kigozi; Veronica Franco; Ronald H Gray; Thomas C Quinn; Susan H Eshleman; Oliver Laeyendecker
Journal:  AIDS Res Hum Retroviruses       Date:  2013-10-25       Impact factor: 2.205

4.  Understanding the clinical and economic outcomes of HIV therapy: the Johns Hopkins HIV clinical practice cohort.

Authors:  R D Moore
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1998

5.  Development of two avidity-based assays to detect recent HIV type 1 seroconversion using a multisubtype gp41 recombinant protein.

Authors:  Xierong Wei; Xin Liu; Trudy Dobbs; Debra Kuehl; John N Nkengasong; Dale J Hu; Bharat S Parekh
Journal:  AIDS Res Hum Retroviruses       Date:  2010-01       Impact factor: 2.205

6.  Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy.

Authors:  Justin R Bailey; Kara G Lassen; Hung-Chih Yang; Thomas C Quinn; Stuart C Ray; Joel N Blankson; Robert F Siliciano
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

Review 7.  Primary HIV infection in infants: impact of highly active antiretroviral therapy on the natural course.

Authors:  A De Rossi
Journal:  J Biol Regul Homeost Agents       Date:  2002 Jan-Mar       Impact factor: 1.711

8.  Early therapy in HIV-1-infected children: effect on HIV-1 dynamics and HIV-1-specific immune response.

Authors:  Marisa Zanchetta; Alessia Anselmi; Daniela Vendrame; Osvalda Rampon; Carlo Giaquinto; Antonio Mazza; Daniele Accapezzato; Vincenzo Barnaba; Anita De Rossi
Journal:  Antivir Ther       Date:  2008

9.  Independent assessment of candidate HIV incidence assays on specimens in the CEPHIA repository.

Authors:  Reshma Kassanjee; Christopher D Pilcher; Sheila M Keating; Shelley N Facente; Elaine McKinney; Matthew A Price; Jeffrey N Martin; Susan Little; Frederick M Hecht; Esper G Kallas; Alex Welte; Michael P Busch; Gary Murphy
Journal:  AIDS       Date:  2014-10-23       Impact factor: 4.177

10.  Estimating incidence from prevalence in generalised HIV epidemics: methods and validation.

Authors:  Timothy B Hallett; Basia Zaba; Jim Todd; Ben Lopman; Wambura Mwita; Sam Biraro; Simon Gregson; J Ties Boerma
Journal:  PLoS Med       Date:  2008-04-08       Impact factor: 11.069
View more
  2 in total

1.  Pattern and Frequency of Seroreactivity to Routinely Used Serologic Tests in Early-Treated Infants With HIV.

Authors:  Thanyawee Puthanakit; Jintanat Ananworanich; Siriwat Akapirat; Supanit Pattanachaiwit; Sasiwimol Ubolyam; Vatcharain Assawadarachai; Panadda Sawangsinth; Thidarat Jupimai; Suvaporn Anugulruengkitt; Monta Tawan; Pope Kosalaraksa; Thitiporn Borkird; Piyarat Suntarattiwong; Suparat Kanjanavanit; Mark S de Souza
Journal:  J Acquir Immune Defic Syndr       Date:  2020-03-01       Impact factor: 3.771

2.  Treatment outcomes and HIV drug resistance of patients switching to second-line regimens after long-term first-line antiretroviral therapy: An observational cohort study.

Authors:  Pi Cao; Bin Su; Jianjun Wu; Zhe Wang; Jiangzhou Yan; Chang Song; Yuhua Ruan; Hui Xing; Yiming Shao; Lingjie Liao
Journal:  Medicine (Baltimore)       Date:  2018-07       Impact factor: 1.889
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.